Solid Biosciences Inc.
Income Statement
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Revenue | $8.1M | $13.6M | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $78.4M | $58.7M | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| SG&A Expense | $28.9M | $27.1M | $21.6M | $24.6M | $17.7M | $15.0M | $5.5M |
| Operating Income | $-106.5M | $-72.3M | $-88.4M | $-119.3M | $-75.7M | $-54.9M | $-25.6M |
| Operating Margin | -1,315.2% | -530.5% | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | — | — |
| Net Income | $-86.0M | $-72.2M | $-88.3M | $-117.2M | $-74.8M | $-52.1M | $-21.5M |
| Net Margin | -1,062.3% | -530.0% | — | — | — | — | — |
| EPS (Basic) | $-2.53 | $-2.54 | $-3.19 | $-0.36 | $-0.28 | $-0.36 | $-1.27 |
| EPS (Diluted) | $-2.53 | $-2.54 | $-3.19 | $-0.36 | $-0.28 | $-0.36 | $-1.27 |
| Shares Outstanding (Basic) | 34.0M | 28.5M | 27.7M | 367.9M | 283.5M | 0 | — |
| Shares Outstanding (Diluted) | 34.0M | 28.5M | 27.7M | 367.9M | 283.5M | 0 | — |
| Dividends Per Share | — | — | — | — | — | — | — |